Circassia Pharmaceuticals Plc Issue of Equity (0762Y)
03 May 2019 - 11:18PM
UK Regulatory
TIDMCIR
RNS Number : 0762Y
Circassia Pharmaceuticals Plc
03 May 2019
Circassia Pharmaceuticals plc
Issue of Equity
Oxford, UK - 3 May 2019 - Circassia Pharmaceuticals plc
("Circassia" or the "Company") (LSE: CIR), a specialty
pharmaceutical company focused on respiratory disease, today
announces that it has issued and allotted 177,405 new ordinary
shares of 0.08p pence each in the Company ("Ordinary Shares") at
the volume weighted average closing price of the Company's Ordinary
Shares for the past five trading days in lieu of advisory services
to the Company.
Application has been made for the new Ordinary Shares to be
admitted to trading, which is expected to be on or around 9 May
2019. The new Ordinary Shares will rank pari passu with the
existing Ordinary Shares of the Company.
Following this issue of Ordinary Shares, the Company's issued
share capital will comprise of 375,048,054 Ordinary Shares
(including the 177,405 new Ordinary Shares). The above figure may
be used by shareholders as the denominator for the calculations by
which they will determine whether they are required to notify their
interest, or a change to their interest, in the Company under the
AIM Rules.
Contacts
Circassia
Steve Harris, Chief Executive Officer Tel: +44 (0) 1865 405
560
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
Peel Hunt (Nominated Adviser and Joint Broker)
James Steel / Dr Christopher Golden Tel: +44 (0) 20 7418
8900
Numis Securities (Joint Broker)
James Black / Freddie Barnfield Tel: +44 (0) 20 7260 1000
FTI Consulting
Simon Conway / Ciara Martin Tel: +44 (0) 20 3727 1000
About Circassia
Circassia is a world-class specialty pharmaceutical business
focused on respiratory disease. The Company sells its novel,
market-leading NIOX(R) asthma management products directly to
specialists in the United States, United Kingdom, China and
Germany, and in a wide range of other countries through its network
of partners. In the United States, Circassia has a commercial
collaboration with AstraZeneca in which it has the commercial
rights to chronic obstructive pulmonary disease (COPD) treatments
Tudorza(R) and Duaklir(R). Circassia also has the US and Chinese
commercial rights to the late-stage ventilator-compatible nitric
oxide product AirNOvent. For more information please visit
www.circassia.com.
Forward-looking statements
This press release contains certain projections and other
forward-looking statements with respect to the financial condition,
results of operations, businesses and prospects of Circassia. The
use of terms such as "may", "will", "should", "expect",
"anticipate", "project", "estimate", "intend", "continue", "target"
or "believe" and similar expressions (or the negatives thereof) are
generally intended to identify forward-looking statements. These
statements are based on current expectations and involve risk and
uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements. Any of the assumptions underlying these
forward-looking statements could prove inaccurate or incorrect and
therefore any results contemplated in the forward-looking
statements may not actually be achieved. Nothing contained in this
press release should be construed as a profit forecast or profit
estimate. Investors or other recipients are cautioned not to place
undue reliance on any forward-looking statements contained herein.
Circassia undertakes no obligation to update or revise (publicly or
otherwise) any forward-looking statement, whether as a result of
new information, future events or other circumstances.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEXXLFBKEFFBBQ
(END) Dow Jones Newswires
May 03, 2019 09:18 ET (13:18 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024